1. |
Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Longterm survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig [J]. Science, 1992; 257(5071)∶789.
|
2. |
Pearson TC, Alexander DZ, Winn KJ, et al. Transplantation tolerance induced by CTLA4Ig [J]. Transplantation, 1994; 57(12)∶1701.
|
3. |
Selvakumar A, White PC, Dupont B. Genomic organization of the mouse Blymphocyte activation antigen B7 [J]. Immunogenetics,1993; 38(4)∶292.
|
4. |
Bugeon L, Dallman MJ. Costimulation of T cells [J]. Am J Respir Crit Care Med, 2000; 162(4 Pt 2)∶S164.
|
5. |
Lin H, Rathmell JC, Gray GS, et al. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28deficient mice: CTLA4 can function independently of CD28 [J]. J Exp Med, 1998; 188(1)∶199.
|
6. |
Lumsden JM, Roberts JM, Harris NL, et al. Differential requirement for CD80 and CD80/CD86dependent costimulation in the lung immune response to an influenza virus infection [J]. J Immunol, 2000; 164(1)∶79.
|
7. |
Alegre ML, Noel PJ, Eisfelder BJ, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells [J]. J Immunol, 1996; 157(11)∶4762.
|
8. |
Donner H, Seidl C, Braun J, et al. CTLA4 gene haplotypes cannot protect from IDDM in the presence of highrisk HLA DQ8 or DQ2 alleles in German families [J]. Diabetes, 1998; 47(7)∶1158.
|
9. |
Liu Y, Janeway CA Jr. Interferon γ plays a critical role in induced cell death of effector T cell: a possible third mechanism of selftolerance [J]. J Exp Med, 1990; 172(6)∶1735.
|
10. |
Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donorspecific transfusion and antiCD154 monoclonal antibody treatment [J]. J Immunol, 1999; 162(8)∶4983.
|
11. |
Gribben JG, Freeman GJ, Boussiotis VA, et al. CTLA4 mediates antigenspecific apoptosis of human T cells [J]. Proc Natl Acad Sci U S A, 1995; 92(3)∶811.
|
12. |
Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions [J]. J Biol Chem, 1996; 271(43)∶26762.
|
13. |
Karandikar NJ, Vanderlugt CL, Walunas TL, et al. CTLA4: a negative regulator of autoimmune disease [J]. J Exp Med, 1996; 184(2)∶783.
|
14. |
Judge TA, Tang A, Spain LM, et al. The in vivo mechanism of action of CTLA4 Ig [J]. J Immunol, 1996; 156(6)∶2294.
|
15. |
Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a nonhuman primate model of allogeneic pancreatic islet transplantation [J]. J Immunol, 1997; 159(11)∶5187.
|
16. |
Steurer W, Nickerson PW, Steele AW, et al.Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance [J]. J Immunol, 1995; 155(3)∶1165.
|
17. |
Chahine AA, Yu M, Mckernan MM, et al. Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells [J]. Transplantation, 1995; 59(9)∶1313.
|
18. |
O’Rourke RW, Kang SM, Lower JA, et al. A dendritic cell line genetically modified to express CTLA4Ig as a means to prolong islet allograft survival [J]. Transplantation, 2000; 69(7)∶1440.
|
19. |
Gainer AL, Korbutt GS, Rajotte RV, et al. Expression of CTLA4Ig by biolistically transfected mouse islets promotes islet allograft survival [J]. Transplantation, 1997; 63(7)∶1017.
|
20. |
Deng S, Kaucher T, Liu C, et al. Intraarterial delivery of adenoviral vectors to intact pancreata achieves highly efficient [J]. Diabetes, 1998; 47(SA)∶67.
|